Capricor Therapeutics Company Profile (OTCMKTS:CAPR)

About Capricor Therapeutics

Capricor Therapeutics logoCapricor Therapeutics, Inc. is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapeutics. The Company focuses on discovering, developing and commercializing regenerative medicine and large molecule products for the treatment of disease, with a primary focus on the treatment of cardiovascular diseases, including orphan indications. Its product candidate, CAP-1002, a cardiosphere-derived cell product, is being tested in the ALLSTAR Phase II clinical study on patients having suffered a myocardial infarction (MI), while the DYNAMIC clinical study is testing CAP-1002 in patients in the advanced-stage of heart failure. CAP-1002 is also being tested in the HOPE-Duchenne Phase I/II clinical study for use in connection with Duchenne muscular dystrophy-related cardiomyopathy. Cenderitide, a dual receptor natriuretic peptide agonist, is being tested in a Phase II clinical study. Exosomes are nano-sized, membrane-enclosed vesicles.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: OTCMKTS
  • Symbol: CAPR
  • CUSIP:
Key Metrics:
  • Previous Close: $3.30
  • 50 Day Moving Average: $3.65
  • 200 Day Moving Average: $3.56
  • 52-Week Range: $1.88 - $5.40
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -3.80
  • P/E Growth: 0.00
  • Market Cap: $58.35M
  • Outstanding Shares: 17,954,000
Additional Links:
Companies Related to Capricor Therapeutics:

Analyst Ratings

Consensus Ratings for Capricor Therapeutics (OTCMKTS:CAPR) (?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $12.50

Analysts' Ratings History for Capricor Therapeutics (OTCMKTS:CAPR)
Show:
DateFirmActionRatingPrice TargetDetails
7/6/2016HC WainwrightInitiated CoverageBuy$13.00View Rating Details
6/15/2016Roth CapitalInitiated CoverageBuy$12.00View Rating Details
(Data available from 9/28/2014 forward)

Earnings

Earnings History for Capricor Therapeutics (OTCMKTS:CAPR)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/10/2016        
8/15/2016Q2($0.24)($0.26)$1.21 millionViewListenView Earnings Details
5/12/2016Q116($0.19)($0.26)$1.10 millionViewListenView Earnings Details
3/17/2016Q415($0.19)($0.21)$1.10 millionViewN/AView Earnings Details
11/12/2015Q315($0.26)($0.18)$1.10 millionViewN/AView Earnings Details
8/13/2015Q215($0.26)($0.19)$1.10 millionViewN/AView Earnings Details
5/12/2015($0.14)($0.23)ViewN/AView Earnings Details
4/15/2015($0.14)($0.16)ViewN/AView Earnings Details
11/14/2014($0.22)($0.13)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Capricor Therapeutics (OTCMKTS:CAPR)
Current Year EPS Consensus Estimate: $-1.04 EPS
Next Year EPS Consensus Estimate: $-0.86 EPS

Dividends

Dividend History for Capricor Therapeutics (OTCMKTS:CAPR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Capricor Therapeutics (OTCMKTS:CAPR)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/21/2016Sinai Medical Center CedarsMajor ShareholderBuy312,500$3.20$1,000,000.00View SEC Filing  
3/16/2016Anthony BergmannVPBuy2,030$2.40$4,872.00View SEC Filing  
3/16/2016Karen KrasneyEVPBuy4,060$2.40$9,744.00View SEC Filing  
3/16/2016Leland GershellCFOBuy2,100$2.40$5,040.00View SEC Filing  
3/16/2016Linda MarbanCEOBuy10,152$2.40$24,364.80View SEC Filing  
3/16/2016Louis J GrasmickDirectorBuy91,369$2.40$219,285.60View SEC Filing  
3/16/2016Sinai Medical Center CedarsMajor ShareholderBuy416,666$2.40$999,998.40View SEC Filing  
8/20/2015Louis J. GrasmickDirectorBuy11,900$4.11$48,909.00View SEC Filing  
8/19/2015Eduardo Marbanmajor shareholderBuy18,400$4.36$80,224.00View SEC Filing  
1/21/2015Joshua A KazamDirectorBuy7,096$3.52$24,977.92View SEC Filing  
1/21/2015Sinai Medical Center CedarsMajor ShareholderBuy851,546$3.52$2,997,441.92View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Capricor Therapeutics (OTCMKTS:CAPR)
DateHeadline
News IconVeterans to be Among First Patients to Receive Investigational Cell Therapy for Heart Failure Under $10 Million Department of Defense Grant (OTCMKTS:CAPR)
www.newswise.com - September 28 at 8:50 AM
News IconVeterans Among First Patients to Receive Cell Therapy for Heart Failure Under $10 Million Department of Defense Grant (OTCMKTS:CAPR)
www.veteransnewsnow.com - September 27 at 4:01 PM
publicnow.com logoCapricor Therapeutics Awarded $2.4 Million from U.S. Department of Defense to Support Manufacturing Process Development for Therapeutic Exosomes (OTCMKTS:CAPR)
www.publicnow.com - September 26 at 8:51 AM
4-traders.com logoCAPRICOR THERAPEUTICS, INC. : Other Events (form 8-K) (OTCMKTS:CAPR)
www.4-traders.com - September 22 at 9:41 AM
publicnow.com logoCapricor Therapeutics Announces Closing of Public Offerings Raising Approximately $10.0 Million in Net Proceeds (OTCMKTS:CAPR)
www.publicnow.com - September 21 at 4:43 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Other Events (OTCMKTS:CAPR)
biz.yahoo.com - September 21 at 4:43 PM
businesswire.com logoCureDuchenne Celebrates FDA Approval of First Drug for Duchenne Muscular Dystrophy (OTCMKTS:CAPR)
www.businesswire.com - September 20 at 9:55 AM
4-traders.com logoCAPRICOR THERAPEUTICS, INC. : Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits (form 8-K) (OTCMKTS:CAPR)
www.4-traders.com - September 17 at 8:51 AM
streetinsider.com logoCapricor Therapeutics (CAPR) Prices 3M Common Stock Offering for Proceeds of ~$8.7M (OTCMKTS:CAPR)
www.streetinsider.com - September 16 at 3:59 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Other Events, Financial S (OTCMKTS:CAPR)
biz.yahoo.com - September 16 at 3:59 PM
publicnow.com logoCapricor Therapeutics Announces Pricing of Offerings of Common Stock (OTCMKTS:CAPR)
www.publicnow.com - September 16 at 3:59 PM
publicnow.com logoCapricor Therapeutics Announces Proposed Public Offering of Common Stock (OTCMKTS:CAPR)
www.publicnow.com - September 15 at 4:24 PM
News IconCapricor completes patient enrollment in phase I/II HOPE Duchenne clinical trial (OTCMKTS:CAPR)
pharmabiz.com - September 9 at 3:59 PM
publicnow.com logoCapricor Therapeutics Completes Enrollment in Randomized HOPE Clinical Trial in Duchenne Muscular Dystrophy (OTCMKTS:CAPR)
www.publicnow.com - September 7 at 9:44 AM
News IconClinging to the promise of heart stem cell therapy (OTCMKTS:CAPR)
news.heart.org - September 2 at 3:53 PM
News IconNew Market Research Report: Dilated Cardiomyopathy - Pipeline Review, H2 2016 (OTCMKTS:CAPR)
reports.pr-inside.com - September 2 at 8:51 AM
finance.yahoo.com logoCapricor Therapeutics to Present at the NewsMakers in the Biotech Industry Conference (OTCMKTS:CAPR)
finance.yahoo.com - September 1 at 12:32 PM
newsmaker.com.au logoDilated Cardiomyopathy Pipeline Market 2016 Clinical Stage Products Review (OTCMKTS:CAPR)
www.newsmaker.com.au - August 30 at 11:55 AM
News IconAcute Heart Failure - Pipeline Review, H2 2016 - New Market Report (OTCMKTS:CAPR)
reports.pr-inside.com - August 23 at 9:18 PM
News IconCapricor Therapeutics Reports Second Quarter 2016 Financial Results and (OTCMKTS:CAPR)
www.biomedreports.com - August 15 at 9:41 PM
reuters.com logoBRIEF-Capricor Therapeutics Q2 loss per share $0.26 (OTCMKTS:CAPR)
www.reuters.com - August 15 at 9:41 PM
4-traders.com logoCapricor Therapeutics : reports 2Q loss (OTCMKTS:CAPR)
www.4-traders.com - August 15 at 9:41 PM
seekingalpha.com logoCapricor Therapeutics' (CAPR) CEO Linda Marbán on Q2 2016 Results - Earnings Call Transcript (OTCMKTS:CAPR)
seekingalpha.com - August 15 at 9:41 PM
finance.yahoo.com logoCapricor Therapeutics Reports Second Quarter 2016 Financial Results and Provides Clinical Update (OTCMKTS:CAPR)
finance.yahoo.com - August 15 at 4:13 PM
publicnow.com logoInvestor Calendar Invites You to the Capricor Therapeutics Second Quarter 2016 Earnings Conference Call and Webcast Live on Monday, August 15, 2016 (OTCMKTS:CAPR)
www.publicnow.com - August 15 at 11:17 AM
finance.yahoo.com logoCapricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call … (OTCMKTS:CAPR)
finance.yahoo.com - August 13 at 12:02 PM
publicnow.com logoCapricor Therapeutics to Hold Second Quarter 2016 Business Update and Financial Results Conference Call and Webcast on Monday, August 15 at 4:30 p.m. ET (OTCMKTS:CAPR)
www.publicnow.com - August 12 at 12:42 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Regulation FD Disclosure (OTCMKTS:CAPR)
biz.yahoo.com - August 1 at 4:00 PM
publicnow.com logoCapricor Therapeutics Provides Enrollment Update on HOPE Clinical Trial in Duchenne Muscular Dystrophy (OTCMKTS:CAPR)
www.publicnow.com - June 23 at 9:09 AM
finance.yahoo.com logoCapricor Therapeutics to Present at JMP Life Sciences Conference (OTCMKTS:CAPR)
finance.yahoo.com - June 22 at 4:12 PM
streetinsider.com logoCapricor Therapeutics (CAPR) Announces Statistically Significant Data on CAP-1002 in Adv. Heart Failure (OTCMKTS:CAPR)
www.streetinsider.com - June 16 at 4:03 PM
schaeffersresearch.com logoCapricor Therapeutics Inc (CAPR) Stock Soars on Drug Data (OTCMKTS:CAPR)
www.schaeffersresearch.com - June 16 at 4:03 PM
publicnow.com logoCapricor Therapeutics Reports Positive 12-Month Data from the DYNAMIC Clinical Trial (OTCMKTS:CAPR)
www.publicnow.com - June 16 at 10:39 AM
finance.yahoo.com logo8:31 am Capricor Therapeutics: CAP-1002 demonstrates durable efficacy signal over 12 months in patients with advanced heart failure (OTCMKTS:CAPR)
finance.yahoo.com - June 16 at 8:31 AM
finance.yahoo.com logoCoverage initiated on Capricor Therapeutics by ROTH Capital (OTCMKTS:CAPR)
finance.yahoo.com - June 15 at 7:03 AM
fxpips.com logoGaps Down Stocks Highlight – URRE, CAPR, CATB, FLXN, ASC, PAY (OTCMKTS:CAPR)
www.fxpips.com - June 9 at 4:04 PM
4-traders.com logoCAPRICOR THERAPEUTICS, INC. : Submission of Matters to a Vote of Security Holders (form 8-K) (OTCMKTS:CAPR)
www.4-traders.com - June 7 at 4:04 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders (OTCMKTS:CAPR)
biz.yahoo.com - June 6 at 5:31 PM
publicnow.com logoCapricor Therapeutics to Present at 2016 BIO International Convention (OTCMKTS:CAPR)
www.publicnow.com - May 31 at 7:12 AM
capitalcube.com logoCapricor Therapeutics, Inc. :CAPR-US: Earnings Analysis: Q1, 2016 By the Numbers : May 23, 2016 (OTCMKTS:CAPR)
www.capitalcube.com - May 23 at 12:37 PM
4-traders.com logoCAPRICOR THERAPEUTICS : Change in Directors or Principal Officers (form 8-K) (OTCMKTS:CAPR)
www.4-traders.com - February 26 at 1:47 PM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Change in Directors or Principal Officers (OTCMKTS:CAPR)
biz.yahoo.com - February 25 at 6:10 AM
finance.yahoo.com logoCapricor Therapeutics Appoints Leland J. Gershell, M.D., Ph.D. as Chief Financial Officer (OTCMKTS:CAPR)
finance.yahoo.com - February 23 at 9:00 AM
biz.yahoo.com logoCAPRICOR THERAPEUTICS, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits (OTCMKTS:CAPR)
biz.yahoo.com - February 22 at 8:01 AM
finance.yahoo.com logoCapricor Therapeutics Announces the First Patient with Duchenne Muscular Dystrophy-Related Cardiomyopathy Treated with CAP-1002 in the HOPE-Duchenne Phase I/II Clinical Trial (OTCMKTS:CAPR)
finance.yahoo.com - February 22 at 8:00 AM
finance.yahoo.com logoCapricor Therapeutics to Present at 18th Annual BIO CEO & Investor Conference (OTCMKTS:CAPR)
finance.yahoo.com - February 2 at 7:00 AM
finance.yahoo.com logoAlign Technology Tops Q4 Earnings, Revenues; Margins Drop (OTCMKTS:CAPR)
finance.yahoo.com - January 29 at 11:20 AM
finance.yahoo.com logoThermo Fisher Tops Q4 Earnings, Affymetrix Buy in the Cards (OTCMKTS:CAPR)
finance.yahoo.com - January 28 at 2:22 PM
zacks.com logoGNC Unveils 2015 Preliminary Outcome; Earnings Beat Likely (OTCMKTS:CAPR)
www.zacks.com - January 20 at 1:21 PM
noodls.com logoCapricor Therapeutics to Present at the 2015 Piper Jaffray Healthcare Conference (OTCMKTS:CAPR)
www.noodls.com - November 24 at 7:11 AM

Social

Capricor Therapeutics (OTCMKTS:CAPR) Chart for Wednesday, September, 28, 2016


Last Updated on 9/28/2016 by MarketBeat.com Staff